Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Chronic Myeloid Leukemia (CML)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trial Details

NCT number	NCT02363868
Study type	Observational
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase	N/A
Start date	February 2014
Completion date	November 2014

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT01066468` - Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.	Phase 1
	Completed	`NCT00428909` - Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)	Phase 1
	Completed	`NCT04126707` - The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans	Phase 1
	Active, not recruiting	`NCT02061800` - CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant	Phase 1/Phase 2
	Completed	`NCT00488592` - Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers	Phase 2
	Terminated	`NCT03615105` - Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors	Phase 2
	Recruiting	`NCT02790515` - Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation	Phase 2
	Active, not recruiting	`NCT03849651` - TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies	Phase 2
	Withdrawn	`NCT01605981` - Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.	Phase 4
	Completed	`NCT00433745` - Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy	Phase 2
	Not yet recruiting	`NCT04709731` - Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia	Phase 2
	Recruiting	`NCT03481868` - EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	N/A
	Recruiting	`NCT02889003` - Second STOP After Pioglitazone Priming in CML Patients	Phase 2
	Completed	`NCT02733445` - Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib	N/A
	Active, not recruiting	`NCT03746054` - Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality	Phase 3
	Completed	`NCT01667133` - A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)	Phase 1/Phase 2
	Completed	`NCT00720785` - Natural Killer Cells and Bortezomib to Treat Cancer	Phase 1
	Recruiting	`NCT05963061` - Chronic Myeloid Leukemia (CML) Real-Life Database
	Approved for marketing	`NCT01592136` - Expanded Access Program of Ponatinib	N/A